WO2004015100A1 - 炎症性疾患の判定方法 - Google Patents
炎症性疾患の判定方法 Download PDFInfo
- Publication number
- WO2004015100A1 WO2004015100A1 PCT/JP2003/010131 JP0310131W WO2004015100A1 WO 2004015100 A1 WO2004015100 A1 WO 2004015100A1 JP 0310131 W JP0310131 W JP 0310131W WO 2004015100 A1 WO2004015100 A1 WO 2004015100A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- seq
- base
- polymorphism
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Definitions
- the 10th base in the exon 1 base sequence of the LT-a gene shown in SEQ ID NO: 1 is A (c0; exon 110A)
- the L ⁇ - sequence shown in SEQ ID NO: 2 is used.
- the 90th base of the base sequence of intron 1 of the ⁇ gene is G (L ⁇ I intron 1252G)
- the base No. 5 is A (LT- ⁇ exon 3723 ⁇ )
- Genome polymorphism is preferably detected using genomic DNA, but in some cases (ie, when the sequence of the polymorphic site and its adjacent region is identical or completely complementary to the genome), cDNA or mRNA may be detected. Can also be used. Examples of the sample from which the above object is collected include any biological sample, for example, body fluids such as blood, bone marrow fluid, semen, peritoneal fluid, and urine; fibroblast cells such as liver; and hair such as hair. . Genomic DNA and the like can be extracted, purified and prepared from these samples according to a conventional method. (Amplification)
- the detection of the gene polymorphism may be performed by Invader Atsushi.
- the invader oligo and the probe have an invasive structure in which one base overlaps.
- Cleavase overlap end nuclease isolated from Archaeoglobus fulgidus acts on this part, and when the base of the signal probe at the SNP site and the target base are complementary (no SNP), 5,5 of the signal probe is used. The flip is cut.
- an LT- a , IKBL, or BAT1 gene fragment containing at least one single nucleotide polymorphism selected from the group consisting of the above (1) to (5) is introduced into a cell.
- the transcriptional activity of LT-a, IKBL, or BAT1 can be measured.
- Diagnosis of myocardial infarction generally requires two of the following three criteria: (1) a clinical history of chest compressions, pain, or tightness lasting more than 30 minutes; (2) at least one ST-segment elevation greater than 0.1 lmV in normal or second chest induction, (3) elevation in serum creatine kinase concentration greater than twice normal experimental values.
- the subjects were 1,133 patients diagnosed with myocardial infarction based on these criteria. Patients with myocardial infarction ranged in age from 28 to 85 years with an average age of 62.5 years. On the other hand, 1,006 healthy volunteers who volunteered through several medical institutions were used as controls. Control subjects ranged in age from 5 to 88 years with an average age of 38.5 years. All subjects were Japanese.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/523,723 US7754422B2 (en) | 2002-08-08 | 2003-08-08 | Method of judging inflammatory disease |
EP03784608.6A EP1536000B1 (en) | 2002-08-08 | 2003-08-08 | Method of judging inflammatory disease |
JP2004527375A JP4688492B2 (ja) | 2002-08-08 | 2003-08-08 | 炎症性疾患の判定方法 |
AU2003254895A AU2003254895A1 (en) | 2002-08-08 | 2003-08-08 | Method of judging inflammatory disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002231532 | 2002-08-08 | ||
JP2002-231532 | 2002-08-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004015100A1 true WO2004015100A1 (ja) | 2004-02-19 |
Family
ID=31711749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/010131 WO2004015100A1 (ja) | 2002-08-08 | 2003-08-08 | 炎症性疾患の判定方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7754422B2 (ja) |
EP (1) | EP1536000B1 (ja) |
JP (1) | JP4688492B2 (ja) |
KR (1) | KR20050083625A (ja) |
AU (1) | AU2003254895A1 (ja) |
TW (1) | TW200406489A (ja) |
WO (1) | WO2004015100A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005087953A2 (en) * | 2004-03-05 | 2005-09-22 | Applera Corporation | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof |
WO2006073183A1 (ja) * | 2005-01-07 | 2006-07-13 | Riken | 一塩基多型を用いた炎症性疾患の判定方法 |
KR100851971B1 (ko) | 2005-05-21 | 2008-08-12 | 삼성전자주식회사 | 심근 경색에 관련된 유전자 다형성 및 그의 용도 |
WO2009057640A1 (ja) | 2007-10-29 | 2009-05-07 | Riken | Brca1 関連タンパク質(brap)遺伝子内一塩基多型を用いた炎症性疾患の判定方法 |
JP4801596B2 (ja) * | 2004-12-24 | 2011-10-26 | 独立行政法人理化学研究所 | 炎症性疾患の検査方法及び炎症性疾患治療薬のスクリーニング方法 |
US8158351B2 (en) | 2006-06-15 | 2012-04-17 | Riken | Method for determining inflammatory disease |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090226420A1 (en) * | 2005-11-10 | 2009-09-10 | Elizabeth Hauser | Methods of Determining the Risk of Developing Coronary Artery Disease |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6183951B1 (en) | 1997-04-11 | 2001-02-06 | Prometheus Laboratories, Inc. | Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy |
CN1192116C (zh) * | 1999-03-30 | 2005-03-09 | 内诺金有限公司 | 通过在半导体微芯片上进行电斑点印迹检测法分辩单核苷酸多态性 |
JP4111481B2 (ja) | 2000-11-02 | 2008-07-02 | 学校法人日本大学 | 心筋梗塞の遺伝的要因を判定するための方法及びこれに使用されるオリゴヌクレオチド |
WO2003034896A2 (en) | 2001-10-12 | 2003-05-01 | Beth Israel Deaconess Medical Center, Inc. | Methods of diagnosis of autoimmune disease |
JP4668792B2 (ja) * | 2003-08-18 | 2011-04-13 | 独立行政法人理化学研究所 | galectin−2遺伝子内一塩基多型を用いた炎症性疾患の判定方法 |
-
2003
- 2003-08-08 US US10/523,723 patent/US7754422B2/en not_active Expired - Fee Related
- 2003-08-08 TW TW092121894A patent/TW200406489A/zh not_active IP Right Cessation
- 2003-08-08 WO PCT/JP2003/010131 patent/WO2004015100A1/ja active Application Filing
- 2003-08-08 KR KR1020057002377A patent/KR20050083625A/ko active Search and Examination
- 2003-08-08 AU AU2003254895A patent/AU2003254895A1/en not_active Abandoned
- 2003-08-08 EP EP03784608.6A patent/EP1536000B1/en not_active Expired - Lifetime
- 2003-08-08 JP JP2004527375A patent/JP4688492B2/ja not_active Expired - Fee Related
Non-Patent Citations (6)
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005087953A2 (en) * | 2004-03-05 | 2005-09-22 | Applera Corporation | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof |
WO2005087953A3 (en) * | 2004-03-05 | 2006-08-17 | Applera Corp | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof |
JP2009521905A (ja) * | 2004-03-05 | 2009-06-11 | アプレラ コーポレイション | 冠動脈心疾患に関連する遺伝的多型、その検出方法および使用 |
JP4801596B2 (ja) * | 2004-12-24 | 2011-10-26 | 独立行政法人理化学研究所 | 炎症性疾患の検査方法及び炎症性疾患治療薬のスクリーニング方法 |
WO2006073183A1 (ja) * | 2005-01-07 | 2006-07-13 | Riken | 一塩基多型を用いた炎症性疾患の判定方法 |
JPWO2006073183A1 (ja) * | 2005-01-07 | 2008-06-12 | 独立行政法人理化学研究所 | 一塩基多型を用いた炎症性疾患の判定方法 |
US20110097711A1 (en) * | 2005-01-07 | 2011-04-28 | Riken | Method of judging inflammatory disease by using single nucleotdie polymorphism |
JP5089173B2 (ja) * | 2005-01-07 | 2012-12-05 | 独立行政法人理化学研究所 | 一塩基多型を用いた炎症性疾患の判定方法 |
US8518644B2 (en) | 2005-01-07 | 2013-08-27 | Riken | Method of judging inflammatory disease by using single nucleotide polymorphism |
KR100851971B1 (ko) | 2005-05-21 | 2008-08-12 | 삼성전자주식회사 | 심근 경색에 관련된 유전자 다형성 및 그의 용도 |
US8158351B2 (en) | 2006-06-15 | 2012-04-17 | Riken | Method for determining inflammatory disease |
WO2009057640A1 (ja) | 2007-10-29 | 2009-05-07 | Riken | Brca1 関連タンパク質(brap)遺伝子内一塩基多型を用いた炎症性疾患の判定方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1536000B1 (en) | 2013-05-01 |
JPWO2004015100A1 (ja) | 2005-12-02 |
KR20050083625A (ko) | 2005-08-26 |
US20060147920A1 (en) | 2006-07-06 |
TWI326710B (ja) | 2010-07-01 |
AU2003254895A1 (en) | 2004-02-25 |
TW200406489A (en) | 2004-05-01 |
EP1536000A1 (en) | 2005-06-01 |
EP1536000A4 (en) | 2007-01-03 |
US7754422B2 (en) | 2010-07-13 |
JP4688492B2 (ja) | 2011-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110070583A1 (en) | Lsamp gene associated with cardiovascular disease | |
ES2342992T3 (es) | Prediccion de un trastorno inflamatorio asociado con los polimorfismos de los loci de genes il-1. | |
US20100240043A1 (en) | Methods of using genetic variants to diagnose and predict inflammatory bowel disease | |
JP2007507460A (ja) | 炎症性疾患の治療効力と関連している遺伝子多型の使用 | |
JP4688492B2 (ja) | 炎症性疾患の判定方法 | |
JP2003502077A (ja) | ヒトhmg−coaレダクターゼ遺伝子における多型 | |
JP2005278479A (ja) | 関節リウマチ検査用マーカー遺伝子 | |
WO2009055596A2 (en) | Methods of using genetic variants to diagnose and predict metabolic syndrome and associated traits | |
JP5364585B2 (ja) | Brca1関連タンパク質(brap)遺伝子内一塩基多型を用いた炎症性疾患の判定方法 | |
JP5644009B2 (ja) | 一塩基多型を用いた炎症性疾患の判定方法 | |
JP4998874B2 (ja) | 炎症性疾患の判定方法 | |
JP5540340B2 (ja) | 炎症性疾患の判定方法 | |
EP4118236A1 (en) | Therapeutic methods for the treatment of subjects with risk alelles in il33 | |
KR101346476B1 (ko) | 천식 위험도와 연관된 단일염기다형성 마커 및 이의 용도 | |
US20070048763A1 (en) | Polymorphism in the macrophage migration inhibitory factor (MIF) gene as marker for prostate cancer | |
JP2008502341A (ja) | 電位型カリウムチャネルをコードするヒト肥満感受性遺伝子およびその使用 | |
US20070122803A1 (en) | Methods for the detection of polymorphisms in the human oatpf gene | |
Blanckenberg | Molecular genetics of arrhythmogenic right ventricular cardiomyopathy in South Africa | |
WO2010033825A2 (en) | Genetic variants associated with abdominal aortic aneurysms | |
Cunnington | Investigation of the mechanisms mediating genetic susceptibility to cardiovascular disease on chromosomes 9p21 and 2q24 | |
Berisha | Genetics and Genomics of Complex Diseases; Mouse Atherosclerosis Modifier Genes and Human Gene Expression After Bariatric Surgery | |
JP2006149276A (ja) | 喘息の遺伝的素因検査方法 | |
JP2008502340A (ja) | 味覚受容体をコードするヒト肥満感受性遺伝子及びその使用 | |
JPWO2003016570A1 (ja) | IL−1β遺伝子の多型を利用した肝細胞癌の検査方法 | |
WO2006136791A1 (en) | Polymorphisms and haplotypes in p2x7 gene and their use in determining susceptibility for atherosclerosis-mediated diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004527375 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057002377 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003784608 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003784608 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057002377 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2006147920 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10523723 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10523723 Country of ref document: US |